Panel Discussion: A Commercial TCR-T & TCR Bispecific – What’s Next?
Time: 12:00 pm
day: Day 2
Details:
• Discussing engineering methods to alter T-cell or bispecific properties to increase trafficking to tumor sites and enable prolonged killing
• Inhibiting immune suppression pathways to improve cell survival
• Considering implications of multi-engineering on cell viability and patient safety to mitigate adverse effects
